Psychosis Risk
Study register · detail Prospektive Kohortenstudie · Psychosis Risk · 2014

Prognosis of schizophrenia in persons with and without a history of cannabis use.

Harm GRADE Low 80 citations
Samplen = 50.087 Pat.
Duration1973 to 2007
ControlNo history of cannabis use
EndpointHospital readmission rate
Blindingn.a.
DesignProspektive Kohortenstudie
Key finding

Prior cannabis use is associated with a markedly more severe inpatient course of schizophrenia (more readmissions and longer hospitalization).

Summary

n=50.087 Swedish men, 357 schizophrenia cases identified; patients with a history of cannabis use had significantly higher disease burden: median duration of first admission 59 vs. 30 days, readmission rate 10 vs. 4 times, total hospital days 547 vs. 184; OR for >20 readmissions = 3,1 (95% CI 1,3–7,3), OR for admission >2 years = 2,4 (95% CI 1,1–7,4), after adjustment for confounders.

P
PopulationSwedish men with schizophrenia diagnosis (identified as inpatients), n=357 cases from a cohort of 50.087 men (age 18–20 years at assessment of cannabis use)
I
InterventionHistory of cannabis use (documented at age 18–20 years)
C
ControlNo history of cannabis use
O
OutcomeLonger median duration of first hospitalization (59 vs. 30 days), higher median readmission rate (10 vs. 4 times), more total hospital days (547 vs. 184 days); OR for >20 readmissions 3,1 (95%-CI 1,3–7,3), OR for >2 years inpatient treatment 2,4 (95%-CI 1,1–7,4)
Confidence in the evidence
Low

The second of four GRADE levels, the effect estimate is of limited reliability.

Quality profile
Sample size
Blinding
Effect size Harm
Citations / year
Authors
Manrique-Garcia E, Zammit S, Dalman C, Hemmingsson T, Andreasson S, Allebeck P.
DOI 10.1017/s0033291714000191
Design: Prospektive Kohortenstudie
Share
Abstract
<h4>Background</h4>The aim of the study was to determinate whether schizophrenia patients with a history of cannabis use have a different prognosis, with regards to readmission and hospital duration, compared with those without a history of cannabis use.<h4>Method</h4>The present investigation was a cohort study of 50,087 Swedish men with data on cannabis use at the ages of 18-20 years. A total of 357 cases of schizophrenia were identified from in-patient care and followed up from 1973 to 2007.<h4>Results</h4>Schizophrenia patients with a history of cannabis use had a higher median duration of first hospital episode (59 days v. 30 days). Patients with a history of cannabis use had a higher median rate of readmission (10 times v. four times). Also, total number of hospital days was higher in patients with a history of cannabis use compared with those without (547 days v. 184 days). Patients with a history of cannabis use had an increased odds of having more than 20 hospital readmissions compared with non-users [3.1, 95% confidence interval (CI) 1.3-7.3] as well as an increased odds of hospital admission lasting more than 2 years (2.4, 95% CI 1.1-7.4) after controlling for diagnosis of personality disorders, family socio-economic position, IQ score, civil status, place of residence, risky use of alcohol and use of other drugs. Patients with a history of cannabis use were less likely to have paranoid schizophrenia compared with never users (8% v. 17%) in the first admission.<h4>Conclusions</h4>Schizophrenia patients with a history of cannabis use had a significantly higher burden of lifetime in-patient care than non-cannabis users. Not only does cannabis increase the risk of schizophrenia, but also our findings indicate that the course and prognosis of schizophrenia may be more severe than schizophrenia cases in general.

The impediment to action advances action. — Marcus Aurelius